Q3 2021 13F Holders as of 9/30/2021
-
Type / Class
-
Equity / Common Shares, par value CHF 0.08 per share
-
Shares outstanding
-
112M
-
Number of holders
-
51
-
Total 13F shares, excl. options
-
32.8M
-
Shares change
-
-1.85M
-
Total reported value, excl. options
-
$891M
-
Value change
-
-$45.6M
-
Put/Call ratio
-
1.32
-
Number of buys
-
20
-
Number of sells
-
-29
-
Price
-
$27.16
Significant Holders of ADC Therapeutics SA - Common Shares, par value CHF 0.08 per share (ADCT) as of Q3 2021
69 filings reported holding ADCT - ADC Therapeutics SA - Common Shares, par value CHF 0.08 per share as of Q3 2021.
ADC Therapeutics SA - Common Shares, par value CHF 0.08 per share (ADCT) has 51 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 32.8M shares
of 112M outstanding shares and own 29.3% of the company stock.
Largest 10 shareholders include FMR LLC (7.67M shares), Redmile Group, LLC (7.53M shares), JPMORGAN CHASE & CO (3.27M shares), PRICE T ROWE ASSOCIATES INC /MD/ (2.83M shares), ALLIANCEBERNSTEIN L.P. (2.65M shares), Vantage Consulting Group Inc (1.68M shares), Grosvenor Holdings, L.L.C. (1.52M shares), EVENTIDE ASSET MANAGEMENT, LLC (1.31M shares), PICTET ASSET MANAGEMENT SA (1.11M shares), and HHLR ADVISORS, LTD. (500K shares).
This table shows the top 51 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.